Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance, shared a post on X:
“Great talk by my colleague Scott Tykodi on RCC! Adjuvant pembro prolongs OS; 1L Ipi/nivo durable benefit in some patients with 99-month median follow up; no role of anti-PD(L)1 rechallenge based on Contact03 and TiNivo2 trials.”
